Edward Kim Journalist Profile

Articles

Time to vote: Healio | HemOnc Today announce 2025 Disruptive Innovators nominees

1 month ago | healio.com | Edward Kim |Shikha Jain |Eleonora Teplinsky |Katrina Altersitz Wells

Healio | HemOnc Today is excited to announce the nominees for its annual Disruptive Innovators Awards in oncology and hematology. Individuals who changed the face of the specialty and pushed the status quo toward betterment of the field will be recognized during a live event at ASCO Annual Meeting. In this video, awards ceremony co-hosts Shikha Jain, MD, FACP, and Edward S.
Osimertinib for EGFRm Stage III Unresectable NSCLC: The LAURA Trial

Jul 31, 2024 | cancernetwork.com | Joshua K. Sabari |Roy S. Herbst |Edward Kim |Jyoti D Patel |Divya Gupta |Laila Gharzai | +3 more

2 Commerce Drive Cranbury, NJ 08512
Introduction of the Non-Small Cell Lung Cancer Face-Off

Jul 31, 2024 | cancernetwork.com | Joshua K. Sabari |Roy S. Herbst |Edward Kim |Jyoti D Patel |Divya Gupta |Laila Gharzai | +3 more

2 Commerce Drive Cranbury, NJ 08512
Adverse Events Associated With TKIs in HER2-Mutated NSCLC

May 22, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Adverse Events Associated With TKIs in HER2-Mutated NSCLCD. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.
Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

May 15, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities PersistDr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate CancerDr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCCDarolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC

May 8, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities PersistDr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate CancerDr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCCDarolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial CancerAs Orthopedic Oncology Evolves, Caring for the Clinician Must Be a PriorityBelumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHDProphylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

May 1, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLCExperts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.
DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

Apr 24, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
Role of ADCs in HER2-Mutated NSCLC

Apr 24, 2024 | onclive.com | Edgardo S. Santos |Martin F. Dietrich |Edward Kim |Lyudmila A Bazhenova |D. Ross Camidge

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.